MedRx Co., Ltd
Tokyo Stock ExchangeTotal Valuation
MedRx Co., Ltd carries a market capitalization of 3.27B, placing it among publicly traded companies globally. Its enterprise value stands at 4.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.27B |
| Enterprise Value | 4.76B |
Share Statistics
MedRx Co., Ltd currently has 43.95M shares outstanding.
| Shares Outstanding | 43.95M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 27.26, and the price-to-book ratio stands at 20.65.
| PE Ratio | N/A |
| PS Ratio | 27.26 |
| PB Ratio | 20.65 |
| P/TBV Ratio | 2.78 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 18.73 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
MedRx Co., Ltd maintains a current ratio of 52.58, meaning it holds 52.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 52.58 |
| Quick Ratio | 51.13 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -274.22 |
| Return on Assets (ROA) | -23.98 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.73M |
| Effective Tax Rate | N/A |
Stock Price Statistics
MedRx Co., Ltd's stock has declined approximately -27.63158% over the past 52 weeks. The 50-day moving average sits at 64.22, while the 200-day moving average is 102.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | -27.63158% |
| 50-Day Moving Average | 64.22 |
| 200-Day Moving Average | 102.10 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, MedRx Co., Ltd generated 254.05M in revenue and converted that into -511.95M in net income, yielding earnings per share of -13.31. EBITDA reached -590.55M, while operating income came in at -590.55M.
| Revenue | 254.05M |
| Gross Profit | 254.05M |
| Operating Income | -590.55M |
| Pretax Income | -513.68M |
| Net Income | -511.95M |
| EBITDA | -590.55M |
| EBIT | -590.55M |
| Earnings Per Share (EPS) | -13.31 |
Balance Sheet
Total book value stands at 335.27M, with working capital of 2.19B providing operational flexibility.
| Cash & Cash Equivalents | 2.17B |
| Total Debt | N/A |
| Net Debt | -2.17B |
| Equity (Book Value) | 335.27M |
| Book Value Per Share | 8.72 |
| Working Capital | 2.19B |
Margins
MedRx Co., Ltd operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -232.46 and net profit margin of -201.52 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -232.46 |
| Pretax Margin | -202.20 |
| Profit Margin | -201.52 |
| EBITDA Margin | -232.46 |
Scores
MedRx Co., Ltd posts an Altman Z-Score of 92.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 92.00 |